戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e not mediated by direct modification of its latency-associated peptide.
2 anti-MMP-9 antibodies as well as by TGF-beta latency-associated peptide.
3 a role in its interaction with the TGF-beta1 latency-associated peptide.
4 ations to promote alpha(v)beta(6) binding to latency-associated peptide and to the ligand-mimetic ant
5     These cells produced high levels of LAP (latency-associated peptide) and inhibited IL-17 (interle
6 latent complex (LLC) comprised of TGF-beta1, latency-associated peptide, and latent TGF-beta binding
7 mino acid pro region of TGF-beta1, the beta1-latency-associated peptide (beta1-LAP), is noncovalently
8  of Foxp3 or transforming growth factor beta-latency-associated peptide expressed by THi cells.
9                                  Ultimately, latency-associated peptide expressing CD4(+) regulatory
10  pro-TGF-beta protein as measured by surface latency-associated peptide expression but yet were unabl
11 a-dependent biomarker CD103, suggesting that latency-associated peptide expression is not always cong
12 alpha v beta6 (foot-and-mouth-disease virus, latency associated peptide), have a common structure com
13      The protein complex of TGF-beta and its latency-associated peptide is conjugated onto SWCNTs, wh
14 tent TGF-beta complex, which consists of the latency associated peptide (LAP) secreted in non-covalen
15 g growth factor beta (TGF-beta), decorin and latency associated peptide (LAP), to reverse depressed T
16 h plays roles in targeting and activation, a latency associated peptide (LAP), which regulates latenc
17                           We have identified latency-associated peptide (LAP) and IL-1 receptor type
18 gulatory cells have been reported to express latency-associated peptide (LAP) and TGF-beta on the sur
19 beta) is secreted as a latent complex of the latency-associated peptide (LAP) and the mature domain,
20               These Tregs expressed both the latency-associated peptide (LAP) and the PD-1 receptor,
21 s of TGF-beta1 noncovalently associated with latency-associated peptide (LAP) and which can be activa
22          We found that TGF-beta complexed to latency-associated peptide (LAP) is expressed on the cel
23                       We now report that the latency-associated peptide (LAP) of the latent TGF-beta
24 uction of a regulatory T-cell that expresses latency-associated peptide (LAP) on its surface.
25 l subset of CD4(+)CD25(+) Tregs that express latency-associated peptide (LAP) on their cell surface (
26 s and lung-draining lymph nodes that express latency-associated peptide (LAP) on their cell surface b
27 + CD25- LAP+ regulatory T cells that contain latency-associated peptide (LAP) on their surface and th
28  were generated in the presence of TGF-beta1 latency-associated peptide (LAP) or TGF-beta1 neutralizi
29 GF) beta 1 (LC 1-30) but not with TGF-beta 1 latency-associated peptide (LAP) protein (266-278); at 1
30        Nasal anti-CD3 induced a CD4(+)CD25(-)latency-associated peptide (LAP)(+) regulatory T cell th
31 gulatory gammadelta T cells that express the latency-associated peptide (LAP), a membrane-bound TGF-b
32 rs are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from
33 ssing a membrane bound form of TGF-beta, the latency-associated peptide (LAP), and having regulatory
34 ntained markedly higher expression levels of latency-associated peptide (LAP), CD103, PD-1, PD-L1, an
35      It has been reported that pro-TGF-beta, latency-associated peptide (LAP), latent TGF-beta and/or
36 as an inactive (latent) form in complex with latency-associated peptide (LAP), which is disulfide bon
37 TGF-B were higher in myofibroblasts grown on latency-associated peptide (LAP)-coated stiff silicones
38         We induced TGF-beta-dependent CD4(+) latency-associated peptide (LAP)-positive Tregs by oral
39 lly found in the latent form associated with latency-associated peptide (LAP).
40 rface of ex vivo immature human DCs bound by latency-associated peptide (LAP).
41 lly occurring antagonist to TGF-beta1, human latency-associated peptide (LAP).
42 in which it is noncovalently associated with latency-associated peptide (LAP).
43 h its processed propeptide dimer, called the latency-associated peptide (LAP); the complex of the two
44 that express latent membrane-bound TGF-beta (latency-associated peptide [LAP]) and have been shown to
45  which it is bound to its cleaved prodomain (latency-associated peptide [LAP]) and, via LAP, to laten
46 atent complex with its processed propeptide (latency-associated peptide [LAP]).
47 alently associated proregions, also known as latency-associated peptides (LAPs).
48 nhibits binding to all ligands including the latency-associated peptide of TGF-beta.
49 her TGF-beta1-blocking molecule, recombinant latency-associated peptide of TGF-beta1 (rLAP), also rev
50 evented direct binding of fibroblasts to the latency-associated peptide of TGF-beta1 and prevented ac
51 bound to the small latent complex and to the latency-associated peptide of TGF-beta1 and that this bi
52 le proteins (angiopoietin 1, cystatin B, the latency-associated peptide of transforming growth factor
53                                              Latency-associated peptide of transforming growth factor
54 s, such as fibronectin, vitronectin, and the latency-associated peptides of transforming growth facto
55 ed by interactions between integrins and the latency-associated peptide, part of the pro-form of TGFB
56 bioactive TGF-beta entity and its N-terminal latency-associated peptide prodomain.
57 sues as a biologically inactive complex with latency-associated peptide, requires extracellular modif
58           Latent TGF-beta binding protein 1, latency-associated peptide, TGF-beta1, clusterin, von Wi
59 tionally active receptor for fibronectin and latency-associated peptide-TGF-beta1; it mediates attach
60 tly on IL-10(+) (26.3 +/- 5.8%) and on a few latency-associated peptide/TGF-beta1(+) (18.1 +/- 1.9%)
61 e enriched in CD25(high), CD25(+)CD127(low), latency-associated peptide/TGF-beta1, and CCR4-expressin
62 igrate on an alphavbeta6 specific substrate, latency-associated peptide-TGFbeta, to a greater extent
63        TGF-beta1 is noncovalently bound to a latency-associated peptide that is, in turn, covalently
64 anistically, we found that ADAM9 cleaved the latency-associated peptide to produce bioactive transfor
65 interferon-y, interleukin 4, interleukin 22, latency associated peptide-transforming growth factor-B,
66 ic interleukin 10 (IL-10) and membrane-bound latency-associated peptide/transforming growth factor be
67 ed with either antibodies to TGF-beta or the latency associated peptide, which neutralize TGF-beta.
68 ased IGFBP-3 mRNA levels, but treatment with latency-associated peptide, which inactivates secreted T
69 eted as a biologically inactive complex with latency-associated peptide, which must be modified by lo
70 a(6) to the transforming growth factor-beta1 latency-associated peptide with IC(50) values as low as